444

OBI PHARMA INC

No trades
See on Supercharts

4174 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

OBI Pharma, Inc. engages in the development and licensing of novel therapeutic agents for unmet medical needs against cancer. Its products include Adagloxad Simolenin, which is a late-stage novel active immune-oncology Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. The company was founded by Michael N. Chang on April 29, 2002 and is headquartered in Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

4174 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company